3rd Annual Gene Therapy Analytical Development Summit 2021

Memo

As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, the 3rd Annual Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency, quality and safety of gene therapy products. Focused specifically on addressing the unique analytical challenges posed by AAV, lentiviral and non-viral gene therapy products, this technical scientific conference will unite the 'boots on the ground' scientists from the leading companies grappling with these challenges first-hand. With in-depth content on developing clinically relevant potency assays, utilizing next generation sequencing and digital PCR to interrogate your product and uncovering next generation technologies to assess empty vs full capsids, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. Date and Time: November 29, 2021 at 9:00 am to December 02, 2021 at 4:00 pm Prices: 2 Day Conference Only - Drug Developer: USD 2199.00,2 Day Conference + Workshop Day OR Discussion Day - Drug Developer: USD 2997.00,FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Discussion Day - Drug Developer: USD 3795.00,2 Day Conference Only - Standard: USD 3299.00,2 Day Conference + Workshop Day OR Discussion Day - Standard: USD 4297.00,FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Discussion Day - Standard: USD 3299.00 URLs: Tickets: https://go.evvnt.com/860175-2?pid=5569 Brochure: https://go.evvnt.com/860175-3?pid=5569 Speakers: Arden Bond, Senior Scientist, AskBio, Hai Yue, Associate Scientific Director, Bristol Myers Squibb, Irnela Bajrovic, Formulation Scientist, Ask Bio, Larissa Benavente, Senior Scientist Analytical Development, AskBio, Luigi Barbarossa, Senior Research Associate, AVROBIO, Christopher Bravery, Consultant, TBC, Peter Clarner, Scientist, Gene Therapy Accelerator Unit, Biogen, Scott Burger, Consultant, TBC, Vikas Bhat, Senior Scientist, BioMarin, Win Den Cheung, Director Analytical Development, REGENXBIO, Cecilia Della Vale, Associate Director, Analytical Science and Technology (AS&T), PTC Therapeutics, Eric Crampon, Analytics and Bioassay Lead, Takeda, Eugenia Fandunyan, Senior Research Associate, Homology Medicines, Jim Cormier, Head of Bioanalytics, Takeda, Uditha De Alwis, VP Analytical Development and Quality Control, Sarepta, Elizabeth Higgins, Consultant , Huimin Helen Tao, Senior Scientist, Analytical Development, Novartis Gene Therapies, Jonathan Hill, Senior Scientist, Analytical Development, Solid Biosciences, Judith Greengard, Senior Director Assay Development, Adverum, Marina Feschenko, Director, Analytical Development, Biogen, Bill Janssen, Consultant , Jeremy Johnston, Director Analytical Development, AskBio, Joseph Lee, Senior, Director, Rocket Pharmaceuticals, Nicholas Larson, Scientist, Biogen, Santosh Khatwani, Associate Director, Analytical Development, Sangamo Therapeutics, Anthony Leyme, Senior Scientist, Analytical Development, Elevate Bio, Dwayne Neal, Senior Director, Analytical Validation, AVROBIO, Savita Nair, Scientist Bioassay Development, Sangamo Therapeutics, Stuart Nelson, Senior Scientist, Analytical Development, Prevail Therapeutics, Vess Mitaksov, Senior Principal Scientist, Pfizer, Kamila Pytel, Associate Director, Gyroscope Therapeutics, Lyndi Rice, Head of QC Viral Vector, BioMarin, Matt Roberts, Director Analytical Development, GSK, Reena Patel, Scientific Integrator, Janssen, Steven Pincuss, Executive Director, Analytical Development, Neurogene, Aishwarya Shevade, Staff Engineer, Regeneron, Brian Troxell, Associate Director, StrideBio, Ilya Shestopalov, Director Analytical Product Lead, bluebird bio, Mauricio Umana, Associate Director Reg CMC, Biogen, Nolan Sutherland, Scientist, bluebird bio, Kenneth Yancey, Director of Downstream Purification, University of Pennsylvania, Nate Weinstock, Principal Network Lead, Biogen, Nianhuan Yao, BioSeparations Lead, Spark Therapeutics, Peter Webster, Principal Associate Scientist, Solid Biosciences, Yu Wang, Senior Scientist, Biogen, Mimmi Ballard, Group Lead Cell Based Assays, Sana Biotechnology, Speaker to be Confirmed, TBC, Beckman Coulter, Taylor Zhang, Senior Scientific Director, Bristol Myers Squibb, Wei Zhang, Associate Director, Analytical Development, Ultragenyx, Xiaohui Zhao, Bioassay Development Scientist, Biogen, Chen Li, Director, Analytic Sciences, BioAnalytix, Jennifer Chadwick, Vice President, Biologic Development, BioAnalytix, Speaker to be Confirmed, TBC, Charles River Laboratories, Speaker to be Confirmed, TBC, Malvern Panalytical, Speaker to be Confirmed, TBC, Progen, Speaker to be Confirmed, TBC, Qiagen, Speaker to be Confirmed, TBC, Refeyn, Speaker to be Confirmed, TBC, Sartorius, Speaker to be Confirmed, TBC, Sciex, Speaker to be Confirmed, TBC, Stilla Technologies, Speaker to be Confirmed, TBC, Waters Corporation, Yan Zhi, Director Analytical Development, Spirovant Sciences, Qasim Rafiq, Associate Professor Cell and Gene Therapy Bioprocessing, University College London, Yi Pu, Scientist, Biogen